Images List Premium Download Classic

Cirrhosis

Cirrhosis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of ...
Volant Holdings Gmbh
April 12, 2018 - N°20180099001

The present invention is directed to a system characterization of nash that combines modeling and biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash). Said conditions are liver related complications among the array of manifestations of metabolic syndromes, including type 2 ...
Non-invasive method for assessing the presence or severity of liver fibrosis based on a new ...
Universite D'angers
April 12, 2018 - N°20180098728

The present invention relates to for treating for an individual identified as suffering from a liver lesion, preferably liver fibrosis or cirrhosis. The present invention thus relates to a method invention for implementing an adapted patient care for an individual suffering from a liver lesion, preferably liver fibrosis or cirrhosis, said method including the steps of (i) determining in the ...
Ligands that bind tgf-beta receptor ii
Glaxo Group Limited
March 29, 2018 - N°20180086835

The disclosure provides an anti-tgfbetarii immunoglobulin single variable domain. Suitably, an anti-tgfbetarii immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of seq id no:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a ...
Cirrhosis Patent Pack
Download + patent application PDFs
Cirrhosis Patent Applications
Download + Cirrhosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cirrhosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Application of syk serving as therapeutic target for hepatic fibrosis/hepatic cirrhosis
February 15, 2018 - N°20180044685

The present invention discloses an application of syk serving as a therapeutic target for hepatic fibrosis/hepatic cirrhosis. Through experiments, the investor has found that a syk gene has a higher expression during the process of hepatic fibrosis/hepatic cirrhosis, and the progression of hepatic fibrosis is accelerated by promoting activation of the hepatic stellate cells (hscs); and the progression ...
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
Galectin Therapeutics, Inc.
February 15, 2018 - N°20180042958

Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-pdgf receptors; (ii) synaptophysin; (iii) zvegf3; (iv) ccr1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) ...
Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
February 01, 2018 - N°20180030083

Disclosed are deuterated chenodeoxycholic acid derivatives and pharmaceutical compositions containing the deuterated chenodeoxycholic acid derivatives. In particular, disclosed is a deuterated chenodeoxycholic acid derivative of formula (i), or a crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the same. The deuterated chenodeoxycholic acid derivatives of formula (i) can be used to treat and/or ...
Cirrhosis Patent Pack
Download + patent application PDFs
Cirrhosis Patent Applications
Download + Cirrhosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cirrhosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for treating intestinal hyperpermeability
December 21, 2017 - N°20170360736

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic ...
Use of helminthostachys zeylanica, ugonins or flavone-based compounds for the treatment or prevention of metabolic ...
National Research Institute Of Chinese Medicine, Ministry Of Health And Welfare
December 07, 2017 - N°20170348367

Disclosed is a use of helminthostachys zeylanica, ugonins or compounds of formula (i) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose ...
Method of treating liver fibrosis
Chemocentryx, Inc.
December 07, 2017 - N°20170348293

A method of treating liver fibrosis with ccr2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (nafld), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (t2dm) or metabolic syndrome (ms).
Neuregulin in the treatment of fibrotic disorders
Universiteit Antwerpen
November 23, 2017 - N°20170333529

The present invention relates to the treatment of fibrotic disorders. More particularly, the present invention relates to the use of a neuregulin protein in a method treating, preventing and/or delaying fibrotic skin disorders, fibrotic lung disorders or liver cirrhosis.
A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens
Massachusetts General Hospital
October 26, 2017 - N°20170307607

Methods and compositions are described for the diagnosis of primary biliary cirrhosis. Novel autoantigens are described for use in assays which employ test samples from individuals.
High throughput sequencing
October 26, 2017 - N°20170306404

The invention relates to a high throughput method for determining telomere length of mammalian chromosomal dna; primers for use in said method; a kit comprising said primers; use of said method to diagnose or prognose or to determine the risk of developing a telomere shortening disease such as cancer, ageing, neurological disorders including alzheimer's disease, parkinson's disease and other dementias, ...
Adeno-associated viral vectors for the gene therapy of metabolic diseases
Universitat Autonoma De Barcelona
October 12, 2017 - N°20170290926

The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors. The invention also relates to pharmaceutical compositions comprising said vectors.
Cirrhosis Patent Pack
Download + patent application PDFs
Cirrhosis Patent Applications
Download + Cirrhosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cirrhosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Probiotic bifidobacterium adolescentis strains
Chr. Hansen A/s
September 07, 2017 - N°20170252382

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated ...
Cenicriviroc for the treatment of fibrosis
Tobira Therapeutics ,inc.
August 24, 2017 - N°20170239262

The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvate thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (...
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting ...
Yale University
August 17, 2017 - N°20170232027

The invention includes a method of preventing or treating a toxic liver disease or disorder, such as but not limited to non-alcoholic steatohepatitis (nash), liver injury associated with or caused by alcohol consumption in a mammal afflicted with nash, alcoholic hepatitis, drug induced liver injury, primary sclerosing cholangitis, viral hepatitis, liver fibrosis, liver cirrhosis, and other toxic liver conditions, in ...
Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders
The Scripps Research Institute
August 03, 2017 - N°20170217963

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, ...
Small molecule inhibitors of stat3 with anti-tumor activity
University Of Central Florida Research Foundation.
July 20, 2017 - N°20170202795

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e. G., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but ...
Methods and compositions for diagnosis of inflammatory liver disease
Medizinische Hochschule Hannover
June 01, 2017 - N°20170153251

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (e3) levels, either alone or with levels of eotaxin-1 (e1), and optionally, with levels of ccl22 and, further optionally, with levels of il15. These levels can be used to facilitate ...
Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising g protein coupled receptor 119 ...
May 25, 2017 - N°20170143714

Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a gpr119 ligand as an active ingredient. The composition comprising the gpr119 ligand as an active ingredient significantly inhibits the expression of collagen i, transforming growth factor β (tgfβ) and α-smooth muscle actin (α-sma), thereby inhibiting hsc activation, and also significantly ...
Formulations of l-ornithine phenylacetate
Ocera Therapeutics, Inc.
May 18, 2017 - N°20170135973

Some embodiments of the present application are directed to oral formulations of l-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of l-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, ...
Loading